Navigation Links
SuperGen Reports 2008 Third Quarter Financial Results
Date:11/4/2008

including its multi-arm Phase 1b clinical trial, expectations about revenue, gains from sales of non-core assets and operating expenses, expectations regarding the filing of a second IND with the FDA, as well as SuperGen's expectations and successful development of all its pipeline products. Important factors that could cause actual results to differ materially from the expectations reflected in the forward-looking statements include, but are not limited to, risks and uncertainties related to the achievement of developmental milestones with respect to the compounds acquired in the Montigen acquisition, the research and development of MP-470, SGI-1252 or SGI-1776, the satisfaction of the contingencies related to the sale of the worldwide rights to Nipent to Mayne Pharma, and the ability of Eisai to generate global sales of Dacogen. In general, our future success is dependent upon numerous factors, including our ability to generate pre-clinical development candidates for selection into clinical testing, obtaining regulatory approval of product development programs, conducting and completing clinical trials and obtaining regulatory approval of our products and product candidates, and creating opportunities for future commercialization of compounds. Our future revenue and operating and net income or loss could be worse than anticipated if demand for our products is less than expected, or if the introduction of new products is delayed, for any reason, including regulatory delay. References made to the discussion of risk factors are detailed in the Company's filings with the Securities and Exchange Commission including reports on its most recently filed Form 10-K and Form 10-Q. These forward-looking statements are made only as of the date hereof, and we disclaim any obligation to update or revise the information contained in any such forward-looking statements, whether as a result of new information, future events or otherwise.

Contacts:

SuperGen, Inc
'/>"/>

SOURCE SuperGen, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Dr. Audrey F. Jakubowski of SuperGen Retires as Chief Regulatory and Quality Officer
2. SuperGen to Present at Thomas Weisel Partners Healthcare Conference September 5th
3. SuperGen to Announce 2007 Fourth Quarter and Fiscal Year-End Financial Results March 3, 2008
4. SuperGen Reports 2007 Fourth Quarter and Annual Financial Results
5. SuperGen to Announce 2008 First Quarter Financial Results April 28, 2008
6. SuperGen to Webcast 3rd Annual Analyst Day on April 29, 2008
7. SuperGen Reports 2008 First Quarter Financial Results
8. SuperGen to Present at FBR Capital Markets 12th Annual Spring Investor Conference on May 29, 2008
9. SuperGen Reports 2008 Second Quarter Financial Results
10. SuperGen to Present at Merriman 5th Annual Investor Summit on September 15, 2008
11. SuperGen to Present Data at EORTC-NCI-AACR
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... Ale Gicqueau, Founder and President of Clinovo, will ... Align Technology, on “ Conducting Postmarket Registries - Rationale ... Conference and Exhibition on April 25th through April 28th ... poster presentation, Ale Gicqueau and Victor Chen will discuss ... the requirements and resources to conduct the registry, as ...
(Date:3/25/2015)... Agnition announced today that it will be featured ... the first time at 7:30 a.m. CST March 31 ... the extremely important role soil microbes perform in crop ... Catalyst™ technology that enhances soil and plant health for ... again on April 28. , A biochemist at Agnition ...
(Date:3/25/2015)... (PRWEB) March 25, 2015 The ... of smartphones have fuelled social media growth, with ... currently engaged in social networking. Insurance companies are ... communicate with clients and promote a diversity of ... over are increasingly exploiting social networking services as ...
(Date:3/25/2015)... ROCKVILLE, Md. , March 25, 2015 ... been named a finalist for "Best Contract Research Organization" ... by the World Vaccine Congress. This ... as a finalist for the award, winning for "Best ... receiving a "Highly Recommended" distinction in 2013. ...
Breaking Biology Technology:Clinovo Presents at ACRP 2015 in Salt Lake City, Utah on April 25th-28th 2Clinovo Presents at ACRP 2015 in Salt Lake City, Utah on April 25th-28th 3Agnition to be Featured In Upcoming Episode of American Farmer on RFD-TV 2Social Media Role in Global Insurance Industry Examined by Timetric in New Market Research Report Published at MarketPublishers.com 2Social Media Role in Global Insurance Industry Examined by Timetric in New Market Research Report Published at MarketPublishers.com 3Accelovance Nominated for 2015 Vaccine Industry Excellence (ViE) Awards 2
... EMERYVILLE, Calif., Sept. 24 Bionovo, Inc. (Nasdaq: ... at Bionovo, will present the results of a study on the ... for obesity at the 20th Annual Meeting of the North American ... , For most women, the menopausal transition results ...
... CHENGDU, China, Sept. 24 /PRNewswire-Asia-FirstCall/ --, -- Q4 FY ... increased 41.8% to $2.2 Million with diluted EPS of $0.08, ... Income, Increased 32.4% to $7.9 Million vs. ... flow from operations increased 124.8% to $8.3 Million, -- June ...
... ... QTube is a video-based learning tool that offers quick and easy ... Initial QTube videos include imaging techniques such as color overlay, camera/driver ... intensity measurements with multichannel products such as Photometrics Dual View imager. ...
Cached Biology Technology:Bionovo to Present on Novel Female-Specific Drugs for Obesity at the 20th Annual Meeting of the North American Menopause Society 2Bionovo to Present on Novel Female-Specific Drugs for Obesity at the 20th Annual Meeting of the North American Menopause Society 3Tianyin Pharmaceutical Co., Inc. Reports Record Fiscal 2009 Financials With $7.9 Million in Net Income 2Tianyin Pharmaceutical Co., Inc. Reports Record Fiscal 2009 Financials With $7.9 Million in Net Income 3Tianyin Pharmaceutical Co., Inc. Reports Record Fiscal 2009 Financials With $7.9 Million in Net Income 4Tianyin Pharmaceutical Co., Inc. Reports Record Fiscal 2009 Financials With $7.9 Million in Net Income 5Tianyin Pharmaceutical Co., Inc. Reports Record Fiscal 2009 Financials With $7.9 Million in Net Income 6Tianyin Pharmaceutical Co., Inc. Reports Record Fiscal 2009 Financials With $7.9 Million in Net Income 7Tianyin Pharmaceutical Co., Inc. Reports Record Fiscal 2009 Financials With $7.9 Million in Net Income 8Tianyin Pharmaceutical Co., Inc. Reports Record Fiscal 2009 Financials With $7.9 Million in Net Income 9Tianyin Pharmaceutical Co., Inc. Reports Record Fiscal 2009 Financials With $7.9 Million in Net Income 10Tianyin Pharmaceutical Co., Inc. Reports Record Fiscal 2009 Financials With $7.9 Million in Net Income 11Tianyin Pharmaceutical Co., Inc. Reports Record Fiscal 2009 Financials With $7.9 Million in Net Income 12QImaging Introduces "QTube," a Video-based Learning Tool for Scientific & Industrial Digital Imaging 2
(Date:3/10/2015)... 10, 2015   Tute Genomics , pioneer in ... by next-generation sequencing company PrimBio Research Institute ... targeted gene panel interpretation. PrimBio, a certified ... most current technologies to support the work of experts ... offers two types of exome sequencing services: 1) Targeted ...
(Date:3/4/2015)... 2015 Research and Markets ( ... "Global Biometrics Market Forecast and Opportunities, 2020" ... market for biometric authentication systems is projected to ... 2020 The driving forces for this ... government projects and constant development in technology. In ...
(Date:3/2/2015)... , March 2, 2015  Businesses have a ... protection company Tharon Rankins Enterprises has announced the ... an ultra-safe way for businesses to protect their ... transactions. Beconux is a biometric ... Enterprises. Functioning similarly to an ATM machine, the ...
Breaking Biology News(10 mins):PrimBio Research Selects Tute as Whole Exome Analysis Provider, Creating Integrated, End-to-End Solution for Next-Generation Sequencing & Data Analysis 2PrimBio Research Selects Tute as Whole Exome Analysis Provider, Creating Integrated, End-to-End Solution for Next-Generation Sequencing & Data Analysis 3Global Biometrics Market Forecast and Opportunities, 2020 2Global Biometrics Market Forecast and Opportunities, 2020 3Personal Data Protection Company Launches New Product 2
... in a mouse model of Alzheimer's,disease have surprised ... characteristic brain plaques are removed.,Researchers at Washington University ... an antibody for a key component of brain ... the brain where,antibodies cleared plaques, many of the ...
... Hospital Boston and Harvard Medical School have shown how ... changes shape, triggering other changes that allow the AIDS ... in the Feb. 24 issue of the journal Nature, ... approaches. , Researchers led by Howard Hughes Medical Institute ...
... have been contaminated with a non-human molecule that,compromises ... research by investigators at the University of California,San ... Institute in La Jolla,California.,In a study published online ... researchers found that human embryonic stem cells,including those ...
Cached Biology News:Key molecule in plant photo-protection identified 2Key molecule in plant photo-protection identified 3Elusive HIV shape change revealed; Key clue to how virus infects cells 2Current human embryonic stem cell lines contaminated UCSD/Salk team finds 2Current human embryonic stem cell lines contaminated UCSD/Salk team finds 3Current human embryonic stem cell lines contaminated UCSD/Salk team finds 4
SHEEP ANTI HUMAN ESTRONE...
Anti-Goat HRP-DAB Cell & Tissue Staining Kit...
... necessary for the isolation and preparation of Leukocytes ... Kit Components: Erythrocyte Lysis ... 220 mL of buffered ammonium chloride. (NH 4 ... 5113) One bottle containing 220 mL of PBS, ...
ANTI NO-TRYPTOPHAN CONJUGATE...
Biology Products: